Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.
Sep 2026· Cardiology in Review· 0 citations· 39 references
Medicine
TL;DR
Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).
Abstract
Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease, and many high-risk patients do not reach target low-density lipoprotein cholesterol (LDL-C) levels despite conventional therapy. Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9. We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL from inception to April 4, 2026 for randomized controlled trials comparing ongericimab with placebo in dyslipidemia, pooled data using random-effects models, and rated certainty with GRADE. Five double- blind trials (10 intervention-placebo comparisons; 1415 participants), all conducted in China, were included. Ongericimab reduced LDL-C at 12 weeks by 69.39 percentage points relative to placebo (95% confidence interval, -73.67 to -65.11), with sustained reductions at 24 weeks (-68.19; -73.67 to -62.71) and 52 weeks (-68.99; -78.33 to -59.65). At 12 weeks, it also reduced apolipoprotein B (-60.68), non-high-density lipoprotein cholesterol (-66.30), total cholesterol (-46.49), lipoprotein(a) (-45.74), and triglycerides (-25.89), and increased apolipoprotein A1 (8.15) and high-density lipoprotein cholesterol (10.33) (all P < 0.0001). Treatment-emergent adverse events (risk ratio 1.01; 0.90-1.14), serious adverse events (1.52; 0.30-7.58), injection-related adverse events (1.31; 0.45-3.78), and laboratory abnormalities did not differ from placebo.
Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.
Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al.· European Journal of Clinical...· 2 citations
Findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonis...
Muhammad Burhan, Z. Shahid, M. Naveed et al.· The Annals of Pharmacotherap...· 0 citations
ABSTRACT Background Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality, and many high‐risk patients fail to reach LDL‐cholesterol (LDL‐C) targets on statins alone. Evolocumab, a PCSK9 inhibitor, offers potent LDL‐C lowering, but a synthesis of its lipid and clinical benefits in seconda...
Anika Goel, M. Naveed, H. Tandel et al.· Endocrinology, Diabetes & Me...· 0 citations
OBJECTIVE
This study was conducted to evaluate lasmiditan efficacy and cardiovascular (CV) safety in patients with CV risk factors, and provide an updated synthesis of observational evidence on long-term triptan-related CV outcomes.
BACKGROUND
Approximately 20% of patients with migraine have CV contraindications to t...
S. Biswas, S. Vasireddy, Y. Srivastava et al.· Headache· 0 citations
BACKGROUND
Nonstatin low-density lipoprotein (LDL)-cholesterol-lowering therapies are increasingly used in secondary prevention, familial hypercholesterolemia, and statin-intolerant patients, but adverse-event reporting is heterogeneous, and harmonized safety evidence remains limited.
OBJECTIVE
To evaluate the tolera...
A. Matteucci, M. Bonanni, S. D. Di Fusco et al.· Journal of Clinical Lipidolo...· 0 citations
Background Semaglutide is prescribed in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM). However, its potential impact on tumorigenesis has prompted considerable debate. Methods The meta-analysis was conducted in accordance with PRISMA 2020 guidelines. We searched We...
Yuan-Yuan Zhong, Xing Tan, Ling Zhang et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.